Who and Where

Who is looking at NAC in COVID?

Determination of efficacy of N-Acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease

CHA-IRB-1139-05/20

ClinicalTrials.gov ID NCT04419025

THIS STUDY HAS CONCLUDED ENROLLMENT

Phase

Application submission to CHA IRB May 1, 2020

Approval August 7, 2020

Enrollment September 30, 2020

Enrollment Halted May 14, 2021

Principal Investigator (PI)

Melisa Lai-Becker MD

Enrollment Eligibility

Age >= 18 years, not pregnant at time of enrollment; known or suspect COVID-19 disease AND one or more of any influenza-like symptom, including:

  • diarrhea

  • vomiting

  • fever (subjective or measured)

  • chills

  • myalgias

  • fatigue

  • sore throat

  • headache

  • cough

  • nasal/sinus congestion or rhinorrhea

  • shortness of breath

  • chest pain

John Adams MD MPH Internist and Pediatrician, CHA Acute Care/Respiratory Clinic project leader; Instructor, Harvard Medical School

Kerry Blomquist RN Emergency Nurse, CHA Everett Hospital

Pieter Cohen MD Internist, Primary Care, CHA; Associate Professor, Harvard Medical School

Julie Devito PA-C Physician Assistant, CHA Department of Emergency Medicine

Jessica Early MD Family Medicine Physician, Hospitalist, CHA; Assistant Professor, Tufts University School of Medicine

Ellie Grossman MD MPH Primary Care Lead for Behavioral Health Integration; Instructor, Harvard Medical School

Lara Hall MD Family Medicine Physician - Urgent Care, Kaiser Permanente (Oregon)

Rachel Hathaway MD Hospital Medicine Physician. Director, HMS Medicine Sub Internship; Director, CHA Internal Medicine Resident Evaluation; Instructor, Harvard Medical School

Janice N. John PA-C MHS MHCDS Medical Director, CHA Acute Care/Respiratory Clinic; Chief PA, Primary Care; Associate Medical Director, Assembly Square Primary Care

Duncan Kuhn MD Pulmonary & Critical Care Physician, CHA; Pulmonary & Critical Care Physician, North Shore Medical Center (Salem MA); Infectious Diseases specialist; Instructor, Harvard Medical School

Melisa Lai-Becker MD Chief, Everett Emergency Department; Director, Division of Medical Toxicology; Medical Toxicologist, Regional Center for Poison Control and Prevention Serving MA & RI; Medical Toxicologist, Boston Children's Hospital; Assistant Professor, Harvard Medical School

Anna Rabkina MD Family physician, Primary Care, CHA, Instructor, Harvard Medical School

Mary Regan PharmD Director, Clinical and Academic Pharmacy Services; Senior Clinical Pharmacist Specialist – Critical Care; Administrator, ACPE-Accredited CPE Programming

Neha Sandeep PA-C Family Medicine PA, CHA Acute Care/Respiratory Clinic and Primary Care, CHA

Yamini Saravanan MD MHS Clerkship Director, HMS Primary Care; Clerkship Director, HMS Internal Medicine Clerkship; Associate Director, HMS Primary Care Experience; Instructor, Harvard Medical School

Alix Schrager MD Internist, Primary Care, Massachusetts General Hospital (MGH); Instructor in Medicine, Harvard Medical School

Anna Shapiro PA-C Physician Assistant, CHA Primary Care

Linda Shipton MD Infectious Diseases specialist, CHA and Spaulding Rehabilitation Center; Medical Director, Tuberculosis Program, MA DPH, CHA; Assistant Professor, Harvard Medical School

Tom Seufert MD Emergency Physician; Associate Director of Clinical Informatics; Director of Emergency Informatics; Instructor, Harvard Medical School

Lisa Yasi RRT Respiratory Therapist, CHA Everett



Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19

ClinicalTrials.gov Identifier: NCT04545008

Prisma Health and Clemson University

A Study of N-acetylcysteine in Patients With COVID-19 Infection

ClinicalTrials.gov Identifier: NCT04374461

Memorial Sloan Kettering Cancer Center

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients (PRANA)

ClinicalTrials.gov Identifier: NCT04458298

Ashvattha Therapeutics (formerly Orpheris, Inc.)

Inflammatory Regulation Effect of NAC on COVID-19 Treatment (INFECT-19)

ClinicalTrials.gov Identifier: NCT04455243

King Saud University, Saudi Arabia

Clinical Application of Methylene Blue for Treatment of Covid-19 Patients (Covid-19)

ClinicalTrials.gov Identifier: NCT04370288

Mashhad University of Medical Sciences, Iran

Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu

ClinicalTrials.gov Identifier: NCT04279197

ShuGuang Hospital, Shanghai, China

Antioxidant Therapy for COVID-19 Study (GSHSOD-COVID)

ClinicalTrials.gov Identifier: NCT04466657

Obafemi Awolowo University, Nigeria